From Yahoo Finance: 2025-06-23 01:38:00

uniQure N.V. (NASDAQ:QURE) is one of the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reaffirmed its Buy rating and $30 price target for ClearPoint after uniQure N.V. provided a regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease.

uniQure N.V. (NASDAQ:QURE) has partnered with the FDA to expedite the approval process for AMT-130. Lake Street believes AMT-130 could be ClearPoint’s first significant partner asset if trials are successful and FDA approval is granted.

ClearPoint supplies disposables worth nearly $20,000 per AMT-130 infusion, showcasing the financial benefits tied to the therapy’s effectiveness. FDA support could lead to approval by the end of 2026, significantly impacting ClearPoint’s financial position and confirming its focus on neurosurgery and gene therapy.

Lake Street views the regulatory milestone as a positive step for ClearPoint’s role in advancing clinical-stage gene therapies and clarifies the timeline for AMT-130’s clearance.

While uniQure (QURE) shows investment potential, Lake Street suggests AI stocks with greater upside and lower downside risk. For an undervalued AI stock set to benefit from tariffs and onshoring, check out their free report on the best short-term AI stock.

Read more: AMT-130 Could Be Game-Changer For ClearPoint